A Phase 4 interventional study of Varenicline Tartrate and Placebo in Smoking Cessation, sponsored by Pfizer. Completed at 65 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-01.
Sponsored by Pfizer · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 4th largest by enrollment, is one of 11 that started in 2011, is one of 47 in phase 4, and was the 56th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,510 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 4th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 4, and was the 39th registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will determine whether varenicline is safe and helps people to quit smoking through reduction when they are not willing/able to make an abrupt quit attempt.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Varenicline Tartrate
Drug: Placebo
Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
Percentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking
Percentage of participants who remained abstinent from Week 15 to Week 24, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the Nicotine Use Inventory (NUI) and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 15 through 24, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).
Time frame: Week 15 - 24
Percentage of Participants With CO Confirmed 4-Week CA From Smoking
Percentage of participants who remained abstinent from Week 21 to Week 24, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the NUI and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 21 through 24, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).
Time frame: Week 21 - 24
Percentage of Participants With CO Confirmed Long Term CA From Smoking
Percentage of participants who remained abstinent from Week 21 to Week 52, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the NUI and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 21 through 52, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).
Time frame: Weeks 21 - 52
Percentage of Participants With 7-Day Point Prevalence of Smoking Cessation
The 7-day point prevalence of abstinence was defined as being abstinent from smoking and using tobacco products during the last 7 days at Week 12, 24, and 52. The participant's smoking status and other nicotine use was evaluated based on the "last 7 days" questions on the NUI and confirmed by CO expiration. Responders were defined as those, who answered "no" to both questions ("Has the subject smoked any cigarettes (even a puff) in the last 7 days?"; and "Has the subject used any nicotine products and/or other tobacco.... in the last 7 days?") and whose expired CO \< 10 ppm. Missing CO was imputed as negative (CO ≤ 10 ppm).
Time frame: Week 12, 24, and 52
Percentage of Participants With 4-Week Point Prevalence of Smoking Cessation
The 4-week point prevalence of abstinence was defined as being abstinent from smoking and using tobacco products during the last 4 weeks of the study. The participant's smoking status and other nicotine use was evaluated based on the "last 4 weeks" questions on the NUI and confirmed by CO expiration. Responders were defined as those, who answered "no" to both questions ("Has the subject smoked any cigarettes (even a puff) in the last 4 weeks?"; and "Has the subject used any nicotine products and/or other tobacco.... in the last 4 weeks?") and whose expired CO \< 10 ppm. Missing CO was imputed as negative (CO ≤ 10 ppm).
Time frame: Week 52
A total of 1747 participants were screened, whereof 1510 were randomized into the study, and of whom 1493 took at least 1 dose of study drug. Overall, 61 centers in 10 countries received study drug: Australia (4), Canada (6), Czech Republic (6), Germany (6), Egypt (3), United Kingdom (7), Japan (6), Mexico (4), Taiwan (7), and USA (12).
| Milestone | Varenicline | Placebo |
|---|---|---|
| Started | 751 | 742 |
| Completed | 559 | 515 |
| Not completed | 192 | 227 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 6 | 28 |
| Withdrew: Lost to follow-up | 76 | 81 |
| Withdrew: Withdrawal by subject | 54 | 59 |
| Withdrew: Reason not specified | 39 | 43 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Adverse event (ae) related to study drug | 12 | 9 |
| Withdrew: Ae not related to study drug | 1 | 4 |
Percentage of participants who remained abstinent from Week 15 to Week 24, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the Nicotine Use Inventory (NUI) and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 15 through 24, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).
| percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking | 32.1 | 6.9 |
Percentage of participants who remained abstinent from Week 21 to Week 24, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the NUI and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 21 through 24, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).
| percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With CO Confirmed 4-Week CA From Smoking | 37.8 | 12.5 |
Percentage of participants who remained abstinent from Week 21 to Week 52, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the NUI and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 21 through 52, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).
| percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With CO Confirmed Long Term CA From Smoking | 27.0 | 9.9 |
The 7-day point prevalence of abstinence was defined as being abstinent from smoking and using tobacco products during the last 7 days at Week 12, 24, and 52. The participant's smoking status and other nicotine use was evaluated based on the "last 7 days" questions on the NUI and confirmed by CO expiration. Responders were defined as those, who answered "no" to both questions ("Has the subject smoked any cigarettes (even a puff) in the last 7 days?"; and "Has the subject used any nicotine products and/or other tobacco.... in the last 7 days?") and whose expired CO \< 10 ppm. Missing CO was imputed as negative (CO ≤ 10 ppm).
| percentage of participants | Varenicline | Placebo |
|---|---|---|
| Week 12 | 31.2 | 6.7 |
| Week 24 | 43.2 | 17.5 |
| Week 52 | 34.1 | 18.3 |
The 4-week point prevalence of abstinence was defined as being abstinent from smoking and using tobacco products during the last 4 weeks of the study. The participant's smoking status and other nicotine use was evaluated based on the "last 4 weeks" questions on the NUI and confirmed by CO expiration. Responders were defined as those, who answered "no" to both questions ("Has the subject smoked any cigarettes (even a puff) in the last 4 weeks?"; and "Has the subject used any nicotine products and/or other tobacco.... in the last 4 weeks?") and whose expired CO \< 10 ppm. Missing CO was imputed as negative (CO ≤ 10 ppm).
| percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With 4-Week Point Prevalence of Smoking Cessation | 32.8 | 17.3 |
Collected over All AEs (serious and nonserious) were recorded from the date of first dose of study drug (Baseline) up to 30 days after the date of last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline | — | 28/751 (3.7%) | 467/751 (62.2%) |
| Placebo | — | 16/742 (2.2%) | 339/742 (45.7%) |
| Event | Varenicline | Placebo |
|---|---|---|
| Myocardial infarctionCardiac disorders | 0/751 | 2/742 |
| Ovarian cystReproductive system and breast disorders | 2/751 | 0/742 |
| VertigoEar and labyrinth disorders | 0/751 | 1/742 |
| IleusGastrointestinal disorders | 0/751 | 1/742 |
| VomitingGastrointestinal disorders | 0/751 | 1/742 |
| Chest painGeneral disorders | 1/751 | 1/742 |
| CellulitisInfections and infestations | 0/751 | 1/742 |
| Lobar pneumoniaInfections and infestations | 0/751 | 1/742 |
| PeritonitisInfections and infestations | 0/751 | 1/742 |
| ContusionInjury, poisoning and procedural complications | 0/751 | 1/742 |
| Event | Varenicline | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 209/751 | 67/742 |
| NasopharyngitisInfections and infestations | 98/751 | 89/742 |
| Abnormal dreamsPsychiatric disorders | 86/751 | 43/742 |
| InsomniaPsychiatric disorders | 80/751 | 51/742 |
| AnxietyPsychiatric disorders | 52/751 | 65/742 |
| Upper respiratory tract infectionInvestigations | 63/751 | 63/742 |
| HeadacheNervous system disorders | 62/751 | 54/742 |
| FatigueGeneral disorders | 46/751 | 34/742 |
| IrritabilityGeneral disorders | 39/751 | 30/742 |
| ConstipationGastrointestinal disorders | 38/751 | 13/742 |
| Age, Continuous(Years) | Varenicline | Placebo | Total |
|---|---|---|---|
| Mean | 44.7 ± 11.8 | 44.4 ± 12.0 | 44.6 ± 11.9 |
| Sex: Female, Male(Participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| Female | 330 | 321 | 651 |
| Male | 421 | 421 | 842 |
The record gives a start of Jul 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline